Company news
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) news
Every Dianthus Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Dianthus Therapeutics to Participate in Three Investor Conferences During September
September 1, 2026
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
August 3, 2026
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
July 2, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
June 3, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026
Dianthus Therapeutics to Participate in Two Investor Conferences
May 26, 2026
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
May 5, 2026
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwr...
March 12, 2026
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
March 10, 2026
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chro...
March 9, 2026
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and...
March 9, 2026
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
March 9, 2026
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Tria...
March 8, 2026
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
February 24, 2026
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 5, 2026
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With...
December 23, 2025
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
November 24, 2025
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
November 5, 2025
Dianthus Therapeutics to Participate in Four Investor Conferences During November
November 4, 2025
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
October 29, 2025
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase ...
October 16, 2025
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
October 2, 2025
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwr...
September 11, 2025
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
September 9, 2025
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, S...
September 8, 2025
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering
September 8, 2025
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Genera...
September 7, 2025
The Oncology Institute Announces Changes to Board of Directors
August 13, 2025
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
August 7, 2025
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
May 29, 2025
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
May 22, 2025
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
May 12, 2025
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expec...
May 5, 2025
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
April 29, 2025
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
March 11, 2025
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcom...
March 5, 2025
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
February 26, 2025
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
January 30, 2025
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
January 8, 2025
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
November 4, 2024
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnos...
October 15, 2024
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
September 4, 2024
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
June 28, 2024
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
June 12, 2024
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
May 8, 2024
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 3, 2024
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
April 11, 2024
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
March 21, 2024